Jin X, Sun R, Li Z, Wang X, Xiong X, Lu W, Lyu H, Xiao X, Tian Y, Zhang H, Fang Z, Wang L, Zhao M. CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia. haematol [Internet]. 2024Sep.1 [cited 2024Dec.5];109(9):3004-8. Available from: https://haematologica.org/article/view/haematol.2023.284241